A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Anna V. Tinker, Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M. Oza
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-06-01
Edice:	Current Oncology
Témata:	epithelial ovarian cancer PARP inhibitors BRCA homologous recombination repair
On-line přístup:	https://www.mdpi.com/1718-7729/29/6/348
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!